Clinical Oncology Specialist
CurrentPromote the adoption and utilization of Molecular Residual Disease Monitoring (MRD) of solid tumors by ctDNA via PCR built from SNVs identified through whole exome and whole transcriptome NGS of solid tumors with a germline control. -SignateraHighlight the complimentary testing advantages of CGP and Germline as an efficient, tissue-sparing option to.